Amplifying Anti-Cancer mKRAS Immunity for Improvement of Disease- Free Survival
- Leveraging lymph-node-targeted vaccine technology to activate durable anti-tumour immune responses against KRAS-mutant cancers
- Demonstrating clinical progress with KRAS-directed immunotherapy, including prior Phase 1 data and emerging results from a randomized Phase 2 study in pancreatic cancer
- Advancing immunotherapy beyond small-molecule KRAS inhibition to prevent recurrence in high-risk patients following surgery and chemotherapy